DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021. Financial terms of this transaction have not been disclosed.
NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch
KENILWORTH (NJ) (dpa-AFX) - Today s Daily Dose brings you news about Nektar s collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharma s strategic financing; and vTv Therapeutics initiation of a phase 1 multiple ascending dose study of HPP737.
Read on.
1. Nektar Teams Up With Merck
Nektar Therapeutics (NKTR) has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a Phase 2/3 study of Bempegaldesleukin in combination with KEYTRUDA for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck.
Interpace Biosciences Announces Path Forward in Letter to Shareholders forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Dear Shareholders,
As the newly appointed President and CEO of Interpace I want to take a moment to formally introduce myself and share the new vision and mission for this Company as it relates to our core capabilities, growth prospects and directional outlook for this year and beyond. I joined Interpace with significant leadership experience, including with several specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories and Eurofins Scientific, Inc. I bring to the table important experience in developing and implementing successful commercial strategies, short and long term financing options, improving reimbursement, overall corporate efficiency, and employee effectiveness – all critical assets as the Company and product pipeline continue to evolve here at Interpace.
Interpace Biosciences Announces Path Forward in Letter to Shareholders apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.